ArticleAmerican journal of cancer research2019
SGO1 induces proliferation and metastasis of prostate cancer through AKT-mediated signaling pathway.
Article in American journal of cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- SGO1 and SGO2 are Associated With Disease Progression and an Immunosuppressive Microenvironment in Papillary Renal Cell Carcinoma.Cancer medicine · 2026Article
- Identification of novel biomarkers for epithelial ovarian cancer through machine learning and explainable artificial intelligence using in silico and in vitro analysis.Scientific reports · 2025Article
- Shugoshin 1 expression in various cancers: a potential target for therapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Review
- Comprehensive Analysis and Experimental Validation of Single-Cell and Transcriptome Sequencing Reveal SGO2 as a Novel Biomarker for Breast Cancer.Breast cancer (Dove Medical Press) · 2025Article
- Pan-cancer analysis reveals SGO1 as a potential cancer prognostic and immunological biomarker.Journal of Cancer · 2025Article
- Prognosis and biological function of SGOL1 in clear cell renal cell carcinoma: a multiomics analysis.BMC medical genomics · 2024Article
- Sustained Shugoshin 1 downregulation reduces tumor growth and metastasis in a mouse xenograft tumor model of triple-negative breast cancer.Cell division · 2023Article
- The TT Genotype of theCells · 2023Article
- A Review of the Regulatory Mechanisms of N-Myc on Cell Cycle.Molecules (Basel, Switzerland) · 2023Review
- Establishment of Bactrian Camel Induced Pluripotent Stem Cells and Prediction of Their Unique Pluripotency Genes.International journal of molecular sciences · 2023Article
- Article
- SGOL2 is a novel prognostic marker and fosters disease progression via a MAD2-mediated pathway in hepatocellular carcinoma.Biomarker research · 2022Article
- Identification and validation of a potential key gene SGOL1 for poor prognosis in hepatocellular carcinoma based on a bioinformatics approach.Frontiers in oncology · 2022Article
- Deciphering the Role of Shugoshin-Like Protein 1 in Lung Adenocarcinoma: A Comprehensive Analysis andFrontiers in oncology · 2022Article
- Mitotic kinases as drivers of the epithelial-to-mesenchymal transition and as therapeutic targets against breast cancers.Experimental biology and medicine (Maywood, N.J.) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although studies have revealed some of the pathological causes associated with prostate cancer progression, further studies are still needed. Shugoshin 1 (SGO1) is a protein essential for precise chromosome segregation during mitosis and meiosis. However, the role and mechanism of SGO1 in tumors and even prostate cancer is not completely clear. In this study, expression of SGO1 in human prostate tumors were higher than that of adjacent normal tissues and were positively correlated with the poor prognosis of prostate cancer patients. SGO1 expression levels are also higher in several prostate cancer cell lines. In cell experiments, knockdown of SGO1 reduced cell proliferation, migration, and invasion in vitro and in vivo, and also inhibited cell cycle progression of prostate cancer cells. In contrast, ectopic expression of SGO1 has the opposite effects. In addition, knockdown of SGO1 induces apoptosis in prostate cancer cells by promoting cleaved caspase-3, caspase-9, and PARP. Importantly SGO1 function is dependent on AKT. Inhibition of AKT activity by AKT inhibitor abolished the role of SGO1 overexpression in promoting cell proliferation and metastasis. Therefore, SGO1 promotes the proliferation and metastasis of prostate cancer through the AKT pathway, and can be considered as an effective candidate for developing an effective prostate cancer treatment strategy.
Indexed as
Identifiers
31911855PMC6943359W3001800838What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.